5-(benzyloxymethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane | 108670-85-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(benzyloxymethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane
• 英文别名: 1-O-benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol；tert-butyl-[1-[tert-butyl(dimethyl)silyl]oxy-3-phenylmethoxypropan-2-yl]oxy-dimethylsilane
• CAS: 108670-85-5
• 化学式: C₂₂H₄₂O₃Si₂
• 分子量: 410.745
• InChiKey: REBPHRWMURITLM-UHFFFAOYSA-N

物化性质

• 沸点：
  393.7±32.0 °C(Predicted)
• 密度：
  0.924±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.62
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(benzyloxymethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane 在 草酰氯 、 palladium on activated charcoal 、 氢气 、 二甲基亚砜 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 2,3-bis<(tert-butyldimethylsilyl)oxy>propanal
  参考文献：
  名称：

  [EN] ANTIBACTERIAL AGENTS
  [FR] AGENTS ANTIBACTÉRIENS

  摘要：

  提供了化学式（I）的抗菌化合物，以及其立体异构体和药用盐；包含这些化合物的药物组合物；通过给予这些化合物治疗细菌感染的方法；以及制备这些化合物的过程。

  公开号：

  WO2013170030A1
• 作为产物：
  描述：

  溴甲苯 在 咪唑 、 盐酸 、 甲醇 、 4-二甲氨基吡啶 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 7.0h， 生成 5-(benzyloxymethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane
  参考文献：
  名称：

  [EN] ANTIBACTERIAL AGENTS
  [FR] AGENTS ANTIBACTÉRIENS

  摘要：

  提供了化学式（I）的抗菌化合物，以及其立体异构体和药用盐；包含这些化合物的药物组合物；通过给予这些化合物治疗细菌感染的方法；以及制备这些化合物的过程。

  公开号：

  WO2013170030A1

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• Synthesis of racemic fecapentaene-12, a potent mutagen from human feces, and its regioisomer
  作者：A.A.Leslie Gunatilaka、Nobuhiro Hirai、David G.I. Kingston

  DOI：10.1016/s0040-4039(00)94111-x

  日期：1983.1

  Racemic fecapentaene-12 [3-(1,3,5,7,9-dodecapentaenyloxy)-1,2-propanediol (1)] and its regioisomer 2-(1,3,5,7,9-dodecapentaenyloxy)-1,3-propanediol (2) have been synthesized. The latter compound is comparably mutagenic to 1.

  外消旋异戊四烯-12 [3-（1,3,5,7,9-十二碳烯基氧基）-1,2-丙二醇（1）]及其区域异构体2-（1,3,5,7,9-十二碳烯基氧基）-1合成了3-3-丙二醇（2）。后一种化合物相对于1具有致突变性。
• ANTIBACTERIAL AGENTS
  申请人：Achaogen, Inc.

  公开号：US20150175530A1

  公开（公告）日：2015-06-25

  Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

  提供式(I)的抗菌化合物：以及其立体异构体和药物学上可接受的盐；包含这些化合物的制药组合物；通过给予这些化合物的途径来治疗细菌感染的方法；以及制备这些化合物的过程。
• Lipidomics Characterization of Biosynthetic and Remodeling Pathways of Cardiolipins in Genetically and Nutritionally Manipulated Yeast Cells
  作者：Yulia Y. Tyurina、Wenjia Lou、Feng Qu、Vladimir A Tyurin、Dariush Mohammadyani、Jenney Liu、Maik Hüttemann、Michael A. Frasso、Peter Wipf、Hülya Bayir、Miriam. L. Greenberg、Valerian E. Kagan

  DOI：10.1021/acschembio.6b00995

  日期：2017.1.20

  Cardioipins (CLs) are unique tetra-acylated phospholipids of mitochondria and define the bioenergetics, and regulatory functions of these organelles. An unresolved paradox is the high uniformity of CL molecular species (tetra-linoleoyl-CL) in the heart, liver, and skeletal muscles in contrast to their high diversification in the brain. Here, we combined liquid chromatography mass-spectrometry -based phospholipidomics with genetic, and nutritional manipulations to explore CLs biosynthetic Vs postsynthetic remodeling processes in S. cerevisiae yeast cells. By applying the differential phospholipidomics analysis, we evaluated the contribution of Cld1 (CL-specific phospholipase A) and Taz1 (acyl-transferase) as the major regulatory mechanisms of the remodeling process. We further established that nutritional "pressure" by high levels of free fatty acids triggered a massive synthesis of homoacylated molecular species in all classes of phospholipids, resulting in the preponderance of the respective, homoacylated CLs. We found that changes in molecular speciation of CLs induced by exogenous C18-fatty acid's,(C18:1 and C18:2) Wild-type (wt) cells did not occur in any of the remodeling mutant cells, including dd1 Delta, taz1 Delta, and dd1 Delta taz1 Delta. Interestingly, molecular speciation of CLs in wt and double mutant cells dd1 Delta taz1 Delta was markedly different. Given that the bioenergetics functions are preserved in the, double mutant, this suggests that the accumulated MLCL-rather than the changed CL speciation-are the likely major Contributors to the mitochondrial dysfunction in taz1 Delta mutant cells (also characteristic of Barth syndrome): Biochemical studies of Cld1 specificity and computer modeling confirmed the hydrolytic selectivity of the enzyme toward C16-CL substrates and the preservation of C18:1-containing CL species.
• GOVINDAN, S. V.;KINGSTON, DAVID G. I.;GUNATILAKA, A. A. L.;VAN, TASSELL R+, J. NATUR. PROD., 50,(1987) N 1, 75-83
  作者：GOVINDAN, S. V.、KINGSTON, DAVID G. I.、GUNATILAKA, A. A. L.、VAN, TASSELL R+

  DOI：——

  日期：——